Clinical Trial Update: Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) [Phase 3]

View source ↗

Summary

Phase 3 trial updating regorafenib as a third-line or beyond therapy for Gastrointestinal Stromal Tumors (GIST) has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: COMPLETED | Results posted: 2013-10-25